Actively Recruiting
Evaluation of Surovatamig AZD0486 Monotherapy via Intravenous Infusion in Adults with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Led by AstraZeneca · Updated on 2026-10-14
270
Participants Needed
94
Research Sites
234 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the use of surovatamig AZD0486 monotherapy as a treatment for adults with relapsed or refractory B-cell non-Hodgkin lymphoma NHL, specifically follicular lymphoma FL and large B-cell lymphoma LBCL. This Phase 2, global, multi-center, open-label study aims to evaluate the efficacy, safety, and tolerability of surovatamig in participants who have already received at least two prior therapies. Participants will receive surovatamig administered as an intravenous infusion at the recommended Phase 2 dose RP2D. The study consists of two modules Module 1 focuses on relapsed or refractory FL, and Module 2 targets relapsed or refractory LBCL. The treatment is given in cycles, and researchers will monitor patients closely during and after administration to assess response and safety. During the study, participants will undergo various assessments including laboratory tests, imaging to measure lymphoma lesions, and evaluations of treatment response. Researchers will track adverse events and drug levels over time. The primary outcome is the overall response rate, evaluated for up to 24 months in Module 1 and 12 months in Module 2. Secondary outcomes include duration of response, survival measures, and quality of life. Follow-up may continue for up to five years to monitor long-term effects and treatment impact.
CONDITIONS
Brief Title
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here